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Uibjedives. The purpose of this study was to estimate the elect
of as Improved reperfhsion therapy for acute myocardial infarc-
tion on myocardial salvage and ventricular function for anterior
and interior infarctions and to ascertain the sample size required
to detect such an effect.
Backg our d. There are significant direrences in myocardium ut
risk between anterior and inferior infarctions that affect the
benefit of reperfusioa therapy.
hhthadc. We studied 58 patients with acute myocardial infarc-
tion (24 anterior, 34 inferior) treated with intravenous recombi-
nant tissue-type plasminogen activator and angioplasty when
necessary. Tomographic imaging with technetium-99m sestamibi
was performed to measure myocardium at risk, final infarct size
and myocardial salvage and to estimate the beneficial erects of an
improved therapy.
Results. A new therapy that was 30% more elective than
existing therapy (with respect to salvage) would increase salvage
(and reduce mean infarct size) by 5 .2% of the left ventricle and
The most definitive end points for randomized trials of acute
intervention in myocardial infarction are early and late mor-
tality. Multiple randomized trials have demonstrated improved
survival with thrombolytic therapy (1-6). Increasingly large
trials comparing survival with different thrombolytic agents
have Mien reported (7-9) . The use of survival as an end point
in future trials of new thrombolytic agents or adjunctive
therapies will be limited by two considerations: 1) the need for
very large sample sizes, which will limit the number of trials
that can be performed ; and 2) the inability, using this end
point, to demonstrate any differential benefit in survivors . As a
result, some future trials are likely to rely on end points that
attempt to measure infarct size, such as myocardial perfusion
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increase late ejection fraction by only 0 .012 (95rie confidence
interval ICI) 0.009 to 0.015) in inferior infarction and by 0.038
(95% Cl 0.027 to 0 .047) in anterior infarction. If anterior and
inferior infarctions occurred with equal frequency, a sample size
of 140 patients in each treatment group would be required to
detect such a change with 80% power . In a trial of inferior
infarctions alone, a sample size of 236 patients in each treatment
group would be required compared with only 98 patients in a trial
of anterior infarctions alone .
Conclusions. The anticipated mean benefit from an improved
reperfusien therapy in individual patients with inferior infarction
is very small and of questionable clinical significance. The antic.
ipated benefit in anterior infarction is greater and easier to detect .
Future randomized trials should be stratified for infarct location
and should consider the greater absolute benefit of treatment in
anterior infarction.
(J Am Coil Cordial 1994;24:616-23)
imaging (10-12), regional wall motion (13-15), ejection frac-
tion (16-22) or end-systolic volume (22 23). Positive results in
such trials may then justify the performance of large trials
using survival as an end point .
Unfortunately, in trials using such end points related to
infarct size, the benefit of thrombolytic therapy compared with
conventional therapy has been less consistent (4,17-20) . The
apparent discrepancy between improvement in late left ven-
tricular function and reduction in mortality has generated
considerable discussion (24,25) . These inconsistent results
raise concern about the use of these end points in the design of
future randomized trials .
Technetium-99m (Tc-99m) sestamibi (hexakis-2-methoxy-
isohutyl isonitrile) is a new radiopharmaceutical that distrib-
utes according to myocardial blood flow (26,27). It demon-
strates slow washout with minimal redistribution (26) even
after flow is restored 'n an occluded artery (28) . The ability of
Tc-99m sestamibi to assess myocardium at risk and infarct size
has been demonstrated in both animal models of infarction
(28-30) and clinical studies (31-36) . Previous studies from this
laboratory have utilized this measurement tool to investigate
the influence of infarct location on myocardium at risk and
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myocardial salvage in patients receiving acute reperfusion
therapy with either intravenous thrombolytic therapy or pri-
mary angioplasty (37). Myocardium at risk and myocardial
salvage are significantly greater in anterior infarction than in
inferior infarction .
These data appear to have important implications for the
design of future randomized trials that use measurements of
infarct size as an end point to compare different thrombolytic
agents or adjunctive therapies, The purpose of this study was to
measure myocardium at risk, final infarct size and myocardial
salvage in patients treated with intravenous recombinant
tissue-type plasminogen activator (rt-PA) (and angioplasty
when necessary), to estimate the potential effect of improved
therapies on myocardial salvage and ventricular function and
to examine alternative approaches to the design of future
randomized trials .
Methods
Study gioup AA consecutive series of patients was enrolled
in a prospective study of Tc-99m sestaniihi from February 1988
to November 1991 and met the following criteria : 1) chest pain
at least 30 min in duration ; 2) elect rocard &graph ic (ECG) ST
segment elevation ?0.I mV in at least two contiguous leads ; 3)
initiation of intravenous rt-PA therapy within 6 h of the onset
K chest pain; and 4) post menopausal women or men >18
years of age
. Seventy-two patients met these inclusion criteria
The exclusion criteria were I) death during hospital stay
(two patients)
; 2) clinical instability precluding tomographic
imaging (four patients) ; 3) historical or ECG evidence of
previous myocardial infarction (four patients), 4) lateral infarc-
tion (three patients) ; and 5) indeterminate location of infarc-
tion (one patient) . The rernainiag 58 patients were included in
the study group (44 men, 14 women ; mean I± SDI age 58 .4 ±
13.5 years, range 28 to 81) . The mean time to initiation of
therapy was 2 .7 ± 1 .1 Ii from the onset of chest pain . Seventeen
of these patients were included in a previous report from our
laboratory (37) of the effects of infarct location on myocardium
at risk and final infarct size .
Clinical care. All patients were admitted to the coronary
care unit and received standard therapy, including oxygen,
sublingual nitroglycerin and lidocaine and intravenous mor-
phine as necessary
. Low dose aspirin was administered in the
emergency room. In patients without congestive heart failure,
bradycardia or heart block, beta-adrenergic blocking agents
were administered as soon as possible . Intravenous trietoprolol
or esmolol was given acutely. After 24 h, oral therapy with
maintenance metoprolol was begun .
Fourteen patients received 100 mg of intravenous rt-PA
(alteplase) according to previously described methods (38)
.
The remaining 44 patients received an investigational rt-PA
(duteplase) in a total dose of 0
.6 MU/kg over 4 h (39) .
Immediate heparin administration was begun in an attempt
to prevent reocclusion . Full-dose intravenous heparin was
continued for 5 days. The patients subsequently received
12,500 U of heparin subcutaneously every 12 h for the remain-
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der of the hospital stay. Episodes of mild to moderate recur-
rent isehemia during the hospital period were treated medi-
cally as vigorously as required . Coronary angiography and
percutaneous transhirninal coronary angioplasty were per-
formed for recurrent ischernic symptoms with definite ECG
changes, as previously described (40) . Twenty-five patients
underwent coronary angioplasty in hospital that was successful
in 22. Seven patients underwent coronary artery bypass graft
surgery while in hospital, two after unsuccessful angioplasty
.
Radionuclide methods, The radionuclide methods used
have been previously described in detail (32,35,37,41) . In brief,
20 to 30 mCi of Tc-99m scstarnibi was injected intravenously in
all patients before initiation of thrornbolytic therapy and again
6 to 14 days later before hospital discharge (after angioplasty
or bypass surgery . as
previously described)
. One to 8 h after
ir~ieclion of Tc-99ni sestamibi, tomographic radionuclide ac-
quisitions were performed using a rotating gamma camera .
Thirty images were acquired for 40 s each over a 180' arc,
beginning 41 right anterior ohliquc and ending left posterior
oblique .
Single-photon emission computed tomography was per-
formed using standard back-projection algorithms and a
Ramp-}fanning filter . Quantitation of the extent of the left
ventricle with absent perfusion was performed using a live-slice
technique (37). Short-axis slices of the left ventricle were
obtained every 6 mm and normalized to the peak counts in
each slice . The apical and basal slices were chosen using
predetermined rules
. Three intermediate slices were selected
at equal intervals between the apical and basal slices . Circum-
ferential count profiles were generated for these five slices by
identifying the peak counts every 6° around the left ventricle .
Quantitation of the area of absent perfusion was performed
using a threshold technique and standard geometric formulas
P235,411 This five-slice method represents a modification of
our previously described three-slice method, which correlated
closely with perfusion defect size in phantom models (41) . A
similar technique correlated closely with myocardial infarct
size assessed by triphenyl tetrazolium chloride (17C) staining
in animal models of permanent occlusion (29) and reperfusion
(42)
. Using this method, we defined the following :
Myocardium at risk (4It, of left ventricle)
= Acute perfusion defect
;
Final infarct size
	
of left venticle)
= Final perfusion defect
;
Salvage (~i, of left ventricle)
= Acute perfusion defect Final perfusion defect ;
Salvage index =
Acute perfusion defect - Final perfusion defect
617
Acute perfusion defect
in a previous study (35) of 32 patients, final defect size was
closely correlated (r = -0 .81) with 6-week ejection fraction
with a regression equation, as follows
:
618
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Table 1. Technetium-99m Sestamibi Results by Infarct Location, Displayed as Median (25th
Percentile, 75th Percentile)
(95%n confidence interval)
	
(0.045-0 .077)
6-week ejection fraction = 0 .58 - 0.0047
x Final defect size (% of left ventricle).
The 95% confidence limits of the slope of -0 .0047 were
-0.0034 and --0.0059 .
Therefore, if we assume that the observed correlation
represents a causal relation, a reduction in infarct size (final
defect size) of 5% of the left ventricle would be approximately
equivalent to a 0 .024 difference in ejection fraction (95%
confidence interval [CIJ 0 .017 to 0.030).
Possible design strategies for uture trials . We considered
several possible approaches to the design of a rartdomized trial
using salvage (the change in perfusion defect size between
initial and final imaging) as ton end point to compare throm-
bolysis with rt-PA (and angioplasty when necessary) to some
new therapeutic approach. Examples of such a new approach
would include a different thrombolytic agent or a new adjunc-
tive pharmacologic therapy to reduce reperfusion injury . The
three alternative approaches and the assumptions for each
were the following :
Strategy 1. A reduction in mean infarct size (increase in
salvage) for the entire group, ignoring any effect of infarct
location. The number of anterior and inferior infarctions was
arbitrarily assumed to be equal .
Strategy 2. A reduction in infarct size that was proportion-
ally greater for anterior infarctions . Salvage for each infarct
location would improve by the same percent to achieve an
overall given increase in salvage for the entire group . This
assumes that the relative benefit (salvage index) is equal for
anterior and inferior infarctions, as we previously demon-
strated (37)
. The number of anterior and inferior infarctions
was arbitrarily assumed to be equal .
Stratgy 3. Separate trials for both anterior and inferior
infarctions (with the same relative benefit in both trials) . Such
*Anterior versus inferior myocardial infarction (MI);
EF ejection fraction ; LV = left ventricle .
(11.033
•-
0 .057) (0 .1162-0 .107)
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estimates demonstrate the extreme limits for a study group
dominated by anterior and inferior infarctions rather than a
group with equal numbers of each, as assumed in strategies I
and 2 .
Calculation of sample size and percent improvement in
treatment effect . For each of the three strategies, we calcu-
lated the number of patients needed in each treatment group
to have 80% power to detect a relative improvement in salvage
of 30% and 50% compared with existing therapy. For each of
the strategies, we calculated the absolute increase in salvage as
a percent of the left ventricle. For sl,ategy I, this increase was
computed for the group as a whole, without any consideration
of infarct location . For strategies 2 and 3, this increase was
computed separately for anterior and inferior infarctions. The
sample size was then calculatorO trom the following formula
(see Appendix) :
2(E(T)j`(FnSn	+	 FiSi)
N=	
(FA
"IA + FI AI)-
where E(T) = expected value of t statistic necessary to achieve
80% power at alpha = 0.05; FA = fraction of patients with
anterior infarction ;
AA
= increase in salvage to be detected for
anterior infarction ; SA = standard deviation of salvage for
anterior infarction ; and N = number of patients per stratum in
each treatment group.
Statistical analysis of thrombolytic data. The group data
are displayed as median (25th percentile, 75th percentile)
(Table 1) because preliminary data analysis indicated that the
data were skewed and did not conform to a normal distribu-
tion. For that reason, a nonparametric Mann-Whitney U test
was used to compare inferior and anterior infarctions . The
mean value and standard deviation are also shown for group
data because they were used in the calculation of expected
benefit and sample size (see Discussion and Appendix) .
All Patients
(n = 58)
Inferior MI
(n = 34)
Anterior MI
(n = 24)
p
Value*
Myocardium at risk
24(14 .47) 18(10.23) 51(32,55 .5)
0.0001
Mean
28 .9
17 .7 44.8
SD 19 .0 10 .4 17.2
Final infarct size (%LV) 10(0,22) 8.5 (0, 17) 11(1,28)
0.20
Mean
13.1 9.6 18 .2
SD
14.8
9 .1 19
.5
Salvage (cLV) 10.5 (3,25) 6 .5 (1, 14) 22 (10 .5, 40) 0.0001
Mean
15.8 8 .2 26 .6
SD
17.3
9 .7 19,9
Salvage index
0.60 (010. 1 .0) 0 1 (11.06, L()) 0.63 (0.26,11 .98) 0.28
Mean
(1.48
0
.38
0.Ci2
SD
0.64 0.77 0 .35
Optimal therapy
Reduction in infarct size (~rLV) 13.1
9.6
18
.2
Improvement in LF
tl.(16I (1.045 41.086
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Results
Technetium-99m sestamibi results . The median myocar-
dium at risk for the entire study group was 24% of the left
ventricle, with a very wide range that extended from 0% to
70% of the left ventricle . Patients with anterior infarctions had
more than twice the amount of myocardium at risk as patients
with inferior infarctions . The final infant size showed a similar
broad range for the entire study group . i he median was 10%
of the left ventricle, but the range extended from 0% to 68% .
Patients with anterior infarctions had a median final infarct
size of 11% of the left ventricle compared with 8.5% for
patients with inferior infarctions . This difference did not
achieve statistical significance (p = 0 .20) . Myocardial salvage
was a median of 10.5% of the left ventricle, with a range -6%
to 68%. Salvage in anterior infarctions was far greater than
that in inferior infarctions (p = 0.0001) . 'The salvage index
ranged from -3 .0 to 1 .0, with a median of 0 .60. The salvage
index wits higher in those patients treated earlier than the
mean of 2.7 h than in those treated later (0 .63 vs. 0 .29, p =
0.03) . The salvage index was somewhat higher in anterior
(0.63) than in inferior (0.41) infarctions, but this difference was
insignificant (p = 0.28) . Two patients with inferior infarction
had markedly negative values (-1 .0 and -3.0, respectively) .
The standard deviation of myocardium at risk, final infarct size
and salvage was approximately twice as great in anterior as in
inferior infarctions .
Expected benefit of perfect therapy. For an optimal ther-
apy applied to this patient group, myocardial salvage would
equal myocardium at risk (salvage index 1 .0) . The mean
reduction in infarct size compared with existing therapy would
then be 13 .1% of the left ventricle (Table 1) . On the basis of
the regression relation discussed earlier, the expected improve-
ment in ejection fraction would he 0 .045 in inferior infarctions,
0.086 in anterior infarctions and 0 .061 overall .
Expected benefit of improved therapy . The expected im-
provement in ejection fraction for better, but less than perfect,
therapies is shown in Figure 1 . A therapy that was 30% better
than existing therapy would increase mean salvage by 5 .2% of
the left ventricle and improve ejection fraction by 0 .024 (Table
2). For anterior infarctions, mean salvage would increase by
8.0% of the lei': ventricle, and ejection fraction would increase
by 0.038. For inferior infarctions, mean salvage would increase
by 2.5% of the left ventricle, and ejection fraction would
increase by 0 .012. A therapy that was 50% better than existing
therapy would increase salvage by 13.3% of the left ventricle in
anterior infarctions, 4.1% of the left ventricle in inferior
infarctions and 8.7% of the left ventricle overall (Table 3)
.
Ejection fraction would increase by 0.063 in anterior infarc-
tions, 0.019 in inferior infarctions and 0.041 overall .
Sample size requirements. The sample size requirements
for the alternative strategies for trial design are shown in
Tables 2 and 3. If the effects of infarct location are disregarded
(strategy 1), 62 patients/treatment group are required to detect
a 50% improvement, and 174 patients/treatment group are
required to detect a 30% improvement . When patients with
GIBBONS ET AL.
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Increase in salvage,
Figure 1 . The expected improvement in ejection fraction
(with 95%
confidence limits for the slope relating ejection fraction to final infarct
size) for anterior and inferior myocardial infarction (Ml)
as a function
of the percent increase in salvage compared with existing therapy .
Thus, a 50% increase in salvage implies that salvage for the new
therapy would be 1 .5 times the salvage achieved with existing therapy .
The overall curve assumes that the number of anterior and inferior
infarctions are equal . A fib%, increase in salvage fur anterior infarction
would require a perfect therapy ; that is . the residual infarct size would
he 0 .
both anterior and inferior infarctions are included, and the
effects of infarct location are taken into account, the required
sample sizes are 52 and 140 patients/treatment group to detect
a 50% and 30% improvement, respectively. n contrast, a
separate trial of anterior infarction would require 35 and 98
patients/treatment group to detect an improvement of 50%
and 30%, respectively .
Discussion
Measurement of myocardium at risk . The concept of
myocardium at risk has been well established in multiple
previous animal studies (43-46) . These studies have clearly
demonstrated that the amount of myocardium at risk is highly
variable for a given coronary artery occlusion . The area at risk,
judged by postmortem angiography, correlates with histologic
infarct size, but not perfectly because of the effect of residual
blood flow (presumably collateral flow) in the infarct zone
(46). The first measurements of myocardium at risk in humans
during acute myocardial infarction were performed by Feiring
et al . (47), using intracoronary injection of macroaggregated
albumin
. They confirmed the variability of myocardium at risk,
even when the coronary occlusion occurs at a similar location .
Both animal and clinical studies have demonstrated the
utility of Tc-99m sestamibi for the measurement of myocar-
dium at risk . This new radiopharmaceutical is taken up in
proportion to blood flow (26-28) and does not redistribute
(26,28) . As a result, the patient can undergo injection in the
emergency room, subsequent reperfltsion with thrombolytic
therapy or coronary angioplasty and imaging hours later to
determine the distribution of myocardial perfusion at the time
of injection and the amount of myocardium at risk (31-34)
.
When this radiopharmaceutical is injected after reperfusion,
620	GIBBONS ET AL.
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Table
2. Effect of Different Trial Design Strategies on Increase in Salvage and improvement in
Ejection Fraction for a Therapy 30% Better Than Existing Therapy
Strategy Effect
Inferior MI Anterior MI All MI
Increase in salvage (%LV)
Improvement in EF
(95% confidence interval)
Sample size/treatment group
Increase in salvage (%LV)
Improvement in EF
(95% confidence interval)
Sample size/treatment group
Increase in salvage (%LV)
Improvement in EF
(95% confidence interval)
Sample size/treatment group
Strategy 1 : Equal Numbers of Anterior and Inferior Infarcions (ignoring infarct location)
Abbreviations as in Table 1
.
236
Sample size/treatment group
88
Strategy 2
: Equal Numbers of Anterior and Inferior Infarctions (equal relative benefit)
2 .5
0 .012
(0.(109-0 .015)
70
8 .0
0 .038
(0.027-0
.047)
70
Strategy 3 : Separate'rrials of Inferior and Anterior Infarctions
Sample size/treatment group
Abbreviations as in Table I
.
its uptake does not correlate with blood flow but does correlate
with infarct size (28,30). In clinical studies, the final defect size
measured by this radiopharmaceutical 1 week after infarction
correlates closely with regional wall motion, ejection fraction
and end-systolic volume index measured after infarction
(32,35,36). Because the initial images obtained with this agent
reflect myocardium at risk, and the final images obtained with
this agent reflect infarct size, the difference between the two is
a measure of myocardial salvage .
Efficacy of current therapy. We applied this technique in
the present study to assess the efficacy of a therapeutic strategy
that involves the initial use of intravenous t-PA and the
subsequent use of percutaneous transluminal coronary angio .
plasty for evidence of recurrent ischentia, the so-called conser-
vative strategy (40) . Such a strategy is clearly efficacious, as
irdicated by the mean salvage index of 0.48. The maximal
possible improvement in salvage index with a perfect therapy
98
would only be 0 .52. The expected improvement for a new
therapy would be much more modest . For example, if other
important factors, such as time to reperfusion, collateral
vessels and reperfusion injury did not change, a therapy that
improved arterial patency (that was established early and
maintained) from 60% to 78% would he expected to result in
a 30% (78 - 60160) relative increase in salvage index, com-
pared with existing therapy. The increment in mean salvage
index would be 0.14 (30%
X
0.48). As shown in Table 2, the
reduction in infarct size with such a therapy will be only 5 .2%
of the left ventricle, and the expected increase in ejection
fraction will be 0.024 .
The major implication of these data for patients with
inferior myocardial infarction is that the final infarct size in
patients treated with thrombolysis (and angioplasty when
necessary) is very small . A mean infarct size of only 9 .6% of the
left ventricle will have very little effect on rest ejection fraction .
Table 3. Effect of Different Trial Design Strategies on Increase in Salvage and Improvement in
Ejection Fraction for a Therapy 50% Better Than Existing Therapy
Inferior MI
Anterior MI All MI
Strategy 2: Equal Numbers of Anterior and Inferior Infarctions (equal relative benefit)
4.1
0.019
(0.014-0.024)
26
Strategy 3
: Separate Trials of Inferior and Anterior Infarctions
13.3 8
.7
0.063 0.041
(0.045-0.078)
(0.030-0.051)
26 52
35
5.2
0.024
(0.018-0.031)
174
5
.2
0.024
((1
.018-().031)
140
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Strategy 1
: Equal Numbers of Anterior and Inferior Infarctions (ignoring infarct location)
Increase in salvage (%LV)
-
-
8.7
Improvement in EF -
- 0
.041
(95% confidence interval)
- -
(0.030-0.051)
Sample size/treatment group -
-
62
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Multiple trials of intervention in acute myocardial infarction
have reported a mean ejection fraction in the 50s, a phenom-
enon that has been called the 50% rule
('
48). The small residual
infarct size in inferior infarctions probably explains this obser-
vation because inferior infarctions generally predominate in
most clinical trials . Because the residual infarct size is so small,
the expected mean advantage of any new, improved treatment
in individual patients with inferior myocardial infarction is very
small and of questionable clinical significance . Although it is
certainly feasible to design trials that would anticipate a
clinically significant improvement of, for example, 0 .04 in
ejection fraction (48), such expectations are unrealistic for
inferior infarction because they would require a nearly perfect
therapy.
The implications of these data for the assessment of pa-
tients with anterior myocardial infarction are quite different .
Because the myocardium at risk is so much greater in anterior
infarction, these patients derive a greater absolute benefit from
any therapy . However, there is also greater variability in the
absolute benefit, as indicated by die larger standard deviation
for salvage . Detection of a reduction in infarct size of 8% of
the left ventricle, which is equivalent to an improvement in
ejection fraction of 0.038, requires 98 patients with anterior
infarction in each treatment group . On the basis of this
required sample size, previously published trials have generally
had insufficient power to detect this level of difference in
patients with anterior infarction (49-52) .
Implications for design of future trials . What, then, is the
optimal strategy for the design of randomized trials comparing
different therapies in acute myocardial infarction? The data
argue strongly that the large difference in myocardium at risk
and infarct size between anterior and inferior infarctions must
be recognized and incorporated into the study design . It
appears most reasonable to' tilize strategies that assume that
there will be an equal relative treatment benefit between
anterior and inferior infarctions. Such strategies imply consid-
erable difference in absolute benefit between inferior and
anterior infarctions, as demonstrated in Tables 2 and 3 . A
smaller improvement in therapy than those considered here
would still lead to an absolute benefit in anterior infarctions
that might be clinically meaningful . For example, a new
therapy that was 20% better than the existing therapy would
increase salvage by 5 .3% in anterior infarctions and improve
ejection fraction by 0.025 .
The end point used in these calculations, salvage assessed
by Tc-99m sestamibi, has several advantages. It takes into
account the variability in myocardium at risk, permits the study
of patients with a previous myocardial infarction and allows for
the possibility of infarct extension
. Five patients in our study
group had negative values of salvage, which could represent
either infarct extension or variability in the measurement .
Although savage index would appear to provide a superior
adjustment for myocardium at risk, this ratio is highly sensitive
to small measurement errors when myocardium at risk is small .
This is exemplified by the two patients with inferior myocardial
infarction who had markedly negative values of salvage index .
GIBBONS ET AL .
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As a result, the variability of this end point is far higher than
that of salvage in patients with inferior infarction . Although it
would he advantageous in trials of patients with anterior
infarction (because it would reduce sample size further), it is
less suitable as an end point in trials that include patients with
an inferior infarction or patients with a previous myocardial
infarction .
An alternative approach would be the use of final infarct
size as an end point. This would obviate the need for acute
imaging without a significant increase in sample size because
the variance of final infarct size and salvage are very similar for
both anterior and inferior infarctions (Table 1) . However, the
measurement of final infarct size alone would not permit any
assessment of treatment efficacy in individual patients . More-
over, recent studies using acute imaging have demonstrated
the independent pathophysiologic importance of myocardium
at risk, invasive and noninvasive measures of collateral flow
and time to therapy as determinants of infarct size using
analysis of covariance (53) . Although the calculation of sample
size using analysis of covariance would involve arbitrary as-
sumptions with regard to slope, intercept and variability, such
an analysis should enhance the power of any study in which
acute images were performed . Other end points that attempt
to measure infarct size, such as late ejection fraction, have a
greater variability (standard deviation compared with the
anticipated difference) and therefore larger required sample
sizes . For example, White et al . (49) calculated a required
sample size of 108 patients/treatment group to detect an
improvement in ejection fraction of 0.04, compared with 62
patients in strategy I in Table 3 . Some of the variability in
measurements of ventricular function may reflect the variable
effects of loading conditions, drug therapy and sympathetic
activation .
Study limitations . This study has a number of limitations .
It focuses on myocardial salvage as an end point . There will
certainly be other benefits (25) associated with reperfusion
therapy, as well as other costs, such as cerebral hemorrhage
(48). Some portion of the measured salvage may reflect the
effects of spontaneous reperfusion and collateral flow rather
than thrombolysis. Some portion may be technical, reflecting
changes in wall motion and ventricular geometry . The number
of patients in the experimental group is modest, although the
differences between anterior and inferior infarctions are highly
significant and consistent with previous studies . The 95%
confidence limits in the computed sample sizes in strategy I
include values that are 33% lower and 42% higher . The
regression line relating 6-week ejection fraction and perfusion
defect size is also based on a modest number of patients ; the
95% confidence limits for ejection fraction will cover almost a
twofold range. The imaging technique used was ungated and
therefore potentially degraded by cardiac motion . However,
preliminary data suggest that gated tomography provides very
similar results (54) .
Areas of the left ventricle with poor
mechanical function and severely reduced uptake of Tc-99m
sestamibi are not necessarily fibrotic but could represent
hibernating myocardium (55).
Further studies with positron
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emission tomography may provide insight into this
possibility.
Finally, the calculation of
sample sizes in strategy 3
does not
adjust
for the skewed distribution
of myocardial salvage,
which
will presumably increase the required sample sizes
. However,
the
magnitude of these increases can only
be estimated and
would probably be
modest compared with the 95% confidence
limits. Despite these limitations, we believe that these
data
clearly demonstrate that future trials should
be stratified for
infarct location and should consider the greater absolute
benefit of treatment in anterior infarctions .
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the manuscript by Drs
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Appendix
Detailed Results of Sample Size Calculations
The basic formula for calculating a stratified t test is the following :
E(T)
FA
I%A
+
F
t
4 1
= -	
~(FA)'SA(2/N) +
( F1)- S1(21N)
where E(T) = expected value of the i statistic
; FA = fraction of
patients with anterior infarctions ; S, = standard deviation of
salvage
for anterior infarct;ons ; N = number of patients per stratum in each
treatment group ; and 4A = increase in salvage for anterior infarction .
Reexpressing this formula in terms of N gives us the following :
N-
21E(T)l(FnS, +FIST)
(FA A
A
E
Ft It)`
where E(T) = Z ;
It
+ Z t For 80% power at alpha = (U)5 level,
E(T) _ 2 .8
.
For example, to calculate the ,,ample size for a therapy that was
30% better than existing therapy. using strategy 2 ofTable 2 we do the
following
. Using the previous formula for N and assuming an equal
proportion of anterior and inferior infarctions (i.e., F,, = F
t = 0
.5),
we
have
2(2.8) t(tt.5)=(19,9)= + (0S)°(9
.7)9
N-
((O.5)(8) + (0.5)(25)12
or N # 70/stratum, or a total of 140
patients for each treatment group .
Sample size calculations for strategies I and 3 are based on the regular,
unstratified t test.
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